Tags

Type your tag names separated by a space and hit enter

A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients.
Eye (Lond). 2007 Feb; 21(2):164-8.E

Abstract

AIM

To compare 6 months of treatment with bimatoprost and timolol in terms of their hypotensive efficacy and secondary effects, including changes in macular thickness and the inflammatory reaction induced in the anterior chamber.

METHODS

A prospective, randomized, parallel-group trial performed on 30 eyes of 30 patients per group. The main outcome measure was the difference between the IOP value taken between the baseline visit and the 6-month-visit. Macular thickness determined through optical coherence tomography and anterior chamber inflammation estimated using the laser flare meter was also evaluated. Adverse events were recorded during the study period.

RESULTS

Bimatoprost treatment gave rise to a significantly lower mean IOP than timolol in all follow-up visits as from the first month (P<0.05). Bimatoprost achieved high percentage IOP reductions from baseline in a significantly higher proportion of patients (P<0.05). Macular thickness and anterior chamber flare failed to vary significantly both between the two groups and within each group during the 6-month evaluation (P>0.05).

CONCLUSIONS

Bimatoprost 0.03% once daily showed a greater efficacy then timolol 0.05% twice daily in patients with elevated IOP. No significant differences were detected in macular thickness or anterior uveitis using optical coherence tomography and laser flare photometry.

Authors+Show Affiliations

Hospital Clinico San Carlos, Madrid, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16254590

Citation

Martin, E, et al. "A 6-month Assessment of Bimatoprost 0.03% Vs Timolol Maleate 0.5%: Hypotensive Efficacy, Macular Thickness and Flare in Ocular-hypertensive and Glaucoma Patients." Eye (London, England), vol. 21, no. 2, 2007, pp. 164-8.
Martin E, Martinez-de-la-Casa JM, Garcia-Feijoo J, et al. A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients. Eye (Lond). 2007;21(2):164-8.
Martin, E., Martinez-de-la-Casa, J. M., Garcia-Feijoo, J., Troyano, J., Larrosa, J. M., & Garcia-Sanchez, J. (2007). A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients. Eye (London, England), 21(2), 164-8.
Martin E, et al. A 6-month Assessment of Bimatoprost 0.03% Vs Timolol Maleate 0.5%: Hypotensive Efficacy, Macular Thickness and Flare in Ocular-hypertensive and Glaucoma Patients. Eye (Lond). 2007;21(2):164-8. PubMed PMID: 16254590.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients. AU - Martin,E, AU - Martinez-de-la-Casa,J M, AU - Garcia-Feijoo,J, AU - Troyano,J, AU - Larrosa,J M, AU - Garcia-Sanchez,J, Y1 - 2005/10/28/ PY - 2005/10/29/pubmed PY - 2007/4/4/medline PY - 2005/10/29/entrez SP - 164 EP - 8 JF - Eye (London, England) JO - Eye (Lond) VL - 21 IS - 2 N2 - AIM: To compare 6 months of treatment with bimatoprost and timolol in terms of their hypotensive efficacy and secondary effects, including changes in macular thickness and the inflammatory reaction induced in the anterior chamber. METHODS: A prospective, randomized, parallel-group trial performed on 30 eyes of 30 patients per group. The main outcome measure was the difference between the IOP value taken between the baseline visit and the 6-month-visit. Macular thickness determined through optical coherence tomography and anterior chamber inflammation estimated using the laser flare meter was also evaluated. Adverse events were recorded during the study period. RESULTS: Bimatoprost treatment gave rise to a significantly lower mean IOP than timolol in all follow-up visits as from the first month (P<0.05). Bimatoprost achieved high percentage IOP reductions from baseline in a significantly higher proportion of patients (P<0.05). Macular thickness and anterior chamber flare failed to vary significantly both between the two groups and within each group during the 6-month evaluation (P>0.05). CONCLUSIONS: Bimatoprost 0.03% once daily showed a greater efficacy then timolol 0.05% twice daily in patients with elevated IOP. No significant differences were detected in macular thickness or anterior uveitis using optical coherence tomography and laser flare photometry. SN - 0950-222X UR - https://www.unboundmedicine.com/medline/citation/16254590/A_6_month_assessment_of_bimatoprost_0_03_vs_timolol_maleate_0_5:_hypotensive_efficacy_macular_thickness_and_flare_in_ocular_hypertensive_and_glaucoma_patients_ L2 - https://doi.org/10.1038/sj.eye.6702149 DB - PRIME DP - Unbound Medicine ER -